Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.51 |
| ▸ | CTSA | P10619 | 3/20 | 0.46 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | DCAF1 | Q9Y4B6 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2872605 | 0.86 | MME (0.64) | MMEMMEL1 | |
| SCHEMBL18672760 | 0.79 | MME (0.73) | MMEMMEL1 | |
| SCHEMBL12317383 | 0.79 | MME (0.73) | MMEMMEL1 | |
| SCHEMBL10260899 | 0.78 | MMEL1 (0.50) | MMECTSAMMEL1TP53THRB | |
| SCHEMBL10197750 | 0.78 | MMEL1 (0.58) | MMEMMEL1 | |
| SCHEMBL16132552 | 0.77 | MME (0.60) | MME | |
| SCHEMBL10259960 | 0.77 | MMEL1 (0.48) | MMECTSAMMEL1TP53THRB | |
| SCHEMBL2875465 | 0.76 | MMEL1 (0.58) | MMEMMEL1 | |
| SCHEMBL2875464 | 0.76 | MMEL1 (0.58) | MMEMMEL1 | |
| SCHEMBL12975592 | 0.76 | MME (0.53) | MMEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MME 3/4885CTSA 105/4885MMEL1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.